Mandate

Biovitrum AB acquires the pharmaceutical company Arexis AB

October 03, 2005

Biovitrum, a Swedish biotech company, acquires Arexis, a privately owned Swedish biotech and pharmaceuticals company, for an undisclosed consideration, from 3i Group Plc, Beijer Investors, Industrifonden, InnovationsKapital, and SEB Företagsinvest.

Vinge acted for Biovitrum AB.
Michael Wigge (responsible partner)
Niclas Bergström (associate)

Related

Vinge advises Sveafastigheter on the establishment of its EMTN programme and issuance of EUR 300 million bonds

Vinge has advised Sveafastigheter AB (publ) as Swedish legal counsel on the establishment of a euro medium-term note programme (the “EMTN programme”) with a framework of EUR 2 billion and the issuance of senior unsecured bonds totalling EUR 300 million under the EMTN programme.
January 23, 2026

Vinge advises EQT AB on its combination with Coller Capital

Vinge advises EQT AB on its acquisition Coller Capital, a global secondaries firm with nearly USD 50 billion in total assets under management across institutional, private wealth and insurance-related capital.
January 22, 2026

Vinge advises Nordic Re-Finance AB on a Swedish railway financing

Vinge has acted as Swedish legal counsel to Nordic Re-Finance AB, a leading lessor of locomotives for rail freight traffic in Scandinavia, in connection with the execution of a EUR 250m debt package fully underwritten by Natixis CIB.
January 21, 2026